FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Abattis Bioceuticals Corp.
1000 - 355 Burrard Street
Vancouver, BC V6C 2G8

Item 2. Date of Material Change

April 30, 2014

Item 3. News Release

A news release dated and disseminated April 30, 2014 at Vancouver, British Columbia, through The Newswire.ca, CSE Markets and SEDAR is attached as Schedule "A".

Item 4. Summary of Material Change

See news release, a copy of which is attached hereto.

Item 5. Full Description of Material Change

See news release, a copy of which is attached hereto.

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

Michael Withrow, President & CEO
Telephone: 604.538.6650

Item 9. Date of Report

May 1, 2014

Schedule “A”

Suite 1000 – 355 Burrand Street
Vancouver, BC V6C 2G8
Tel: 778-896-6536
info@abattis.com

ABATTIS ANNOUNCES SHARES FOR DEBT & CORPORATE PRESENTATION ANNOUNCEMENT

Vancouver, BC – April 30, 2014 - Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE: ATT), The Company wishes to announce that pursuant to two consulting agreements with arm’s length parties, it has issued an aggregate of 33,669 common shares at a deemed price of CAD 0.99/share as consideration for services provided to the Company.

The Company is also pleased to announce that we will be hosting a corporate presentation at The Terminal City Club Metropolitan Room, 837 West Hastings Street Vancouver, between the hours of 2 and 6 pm PST on May 1, 2014. Special guest speakers Georges Laraque and Rene Babi New Products Pre- Release Announcement. Dr. Paula Brown, MMPR Importance of Safety and Standards will be presenting along with Company CEO Mike Withrow. If you are interested in attending please RSVP to Denby Greenslade, Denby.Greenslade@Abattis.com as soon as possible as seating is limited.

About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law's of Canada and Foreign Jurisdictions. For more information, visit the Company’s website at www.abattis.com.
For further information, contact the Company’s CEO, Michael Withrow at (778) 896-6536 or at mike.withrow@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those

currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.